SOURCE: Wall Street News Alert

Wall Street News Alert

April 17, 2008 09:13 ET

Wall Street News Alert: OCOL Is on the Move! April 17, 2008

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Wall Street Capital Funding.

WESTON, FL--(Marketwire - April 17, 2008) - Wall Street News Alert's "stocks to watch" this morning are: Oncolin Therapeutics (OTCBB: OCOL), POZEN Inc. (NASDAQ: POZN), Medarex Inc (NASDAQ: MEDX) and St. Jude Medical, Inc. (NYSE: STJ).

Having announced this week that a poster representing its lead cancer technology was being presented at the annual meeting of The American Association for Cancer Research, Oncolin Therapeutics (OTCBB: OCOL) should have investors monitoring the progress of the company closely. Yesterday after the markets closed, the company issued a press release announcing the addition of Sandra Silberman, Ph.D., M.D., to a growing list of prestigious oncologists and cancer scientists joining its Scientific Advisory Board (SAB).

This should be a great addition for the company, as the press release states that Dr. Silberman is a world-renowned oncologist who received her Ph.D. from the John Hopkins University, an M.D. from Cornell University Medical School, followed by a residency at the NYU Medical Center. Dr. Silberman did further post graduate training as a research fellow at Harvard Medical School / Dana Farber Cancer Institute and as a clinical fellow at Harvard Medical School / Brigham & Women's Hospital.

Dr. Silberman began her illustrious pharmaceutical career at Pfizer where she was a Senior Associate Director in Oncology and was involved in bringing Tarceva® into clinical development. She then went on to Novartis as a Senior Director in Oncology where she was the international clinical leader for Gleevec®, one of the most successful and famous drugs approved in the recent past, with current sales of over $400 Million per year.

Dr. Silberman then joined Esai Medical Research as an Associate Vice President and Global Therapeutic Head of Oncology where she was responsible for organizing their oncology program and initiating multiple drugs into clinical development. Recently, as Chief Medical Officer of Tapestry Pharmaceuticals, she helped develop a new taxane into multiple clinical trials.

Investors are urged to monitor the progress of the company! "We are very excited to have someone of Dr. Silberman's stature and experience join our advisory committee. Her knowledge of basic cancer science, coupled with her extensive knowledge of oncology clinical development and commercialization strategies, adds greatly to the potential success of Oncolin's clinical development program," said Dr. Donald Picker, President and COO.

Prior to the latest press release, the stock closed Wednesday at Forty One cents a share.

For an in-depth profile of Oncolin Therapeutics, visit

POZEN Inc. (NASDAQ: POZN) up 28.2% on 12.9 million shares traded.

POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience.

Medarex Inc (NASDAQ: MEDX) up 4.7% on 2.4 million shares traded.

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases.

St. Jude Medical, Inc. (NYSE: STJ) up 0.9% on 7.8 million shares traded.

St. Jude Medical is dedicated to making life better for cardiac, neurological and chronic pain patients worldwide through excellence in medical device technology and services.

Market Commentary:

"New home construction plummeted in March to the lowest level in 17 years, the Commerce Department reported Wednesday, falling by 11.9 percent to a seasonally adjusted annual rate of 947,000 units, a much bigger decline than economists had been forecasting," stated Sonja Rudd in Wall Street News Alert's daily commentary continued at:

Let Wall Street News Alert help advertise for your company using our effective awareness campaigns. If you're interested in telling your story, we can help. Contact us at or see our services at

WSNA's email alert service is free to those investors who sign up on the WSNA home page. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to Special Situation companies that have the potential of showing increased activity. The Wall Street News Alert home page has experienced over 100 million hits. To subscribe to this free service, visit the Wall Street News Alert home page at and select the "join now" button.

*** It has come to the attention of Wall Street News Alert (WSNA), that various persons or companies distribute faxes bearing similar names to Wall Street News Alert. Wall Street News Alert is not affiliated with faxes bearing names such as: Wall Street Stock Alert, Wall Street Investor Alert, Wall Street News Alert or any other fax using various combinations of the generic words Wall Street.***

Wall Street News Alert is a division of Wall Street Capital Funding LLC (WSCF). WSCF also maintains a contractual, working relationship with Stock Market Alerts LLC and its Wall Street Enews brand. WSCF is not a registered broker/dealer and may not sell, offer to sell or offer to buy any security. WSCF profiles are not a solicitation or recommendation to buy, sell or hold securities. An offer to buy or sell can be made only with accompanying disclosure documents from the company offering or selling securities and only in the states and provinces for which they are approved. The material in this release is intended to be strictly informational. The companies that are discussed in this release have not approved the statements made in this release nor approved the timing of this release. All statements and expressions are the sole opinion of WSCF and are subject to change without notice. Information in this release is derived from a variety of sources including that company's publicly disseminated information, third parties and WSCF research. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. WSCF disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. The release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. WSCF is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment if they make a purchase in WSCF profiled stocks.

This profile is not without bias, and is a paid release. WSCF has been compensated for dissemination of company information on behalf of one or more of the companies mentioned in this release. WSCF has been compensated Nineteen Thousand Dollars for coverage of Oncolin Therapeutics (OTCBB: OCOL), previously known as Edgeline Holdings, Inc., by the company, for services provided including dissemination of company information in this release. Prior to the name and symbol change, WSCF was previously compensated for services rendered in 2008 and 2007; the previous compensation can be viewed by looking at a previous WSNA, ELHI press release. WSCF holds no shares of the stock. WSCF may receive additional compensation for extension of its services. Any additional compensation will be disclosed at such time that WSCF is aware of a client's desire to extend the original services. WSCF may have received shares of a company profiled in this release prior to the dissemination of the information in this release. WSCF may immediately sell some or any shares in a profiled company held by WSCF and may have previously sold shares in a profiled company held by WSCF. WSCF's services for a company may cause the company's stock price to increase, in which event WSCF would make a profit when it sells its stock in a company. In addition, WSCF's selling of a company's stock may have a negative effect on the market price of the stock.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WSCF undertakes no obligation to update such statements.

Contact Information